SEARCH

SEARCH BY CITATION

References

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence society. Neurourol. Urodyn. 2002; 21: 16778.
  • 2
    Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we need urodynamics? Neurourol. Urodyn. 2003; 22: 1058.
  • 3
    Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J. Urol. 2003; 169: 52934.
  • 4
    van Brummen HJ, Heintz APM, van der Vaart CH. The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol. Urodyn. 2004; 23: 3842.
  • 5
    Homma Y, Kakizaki H, Gotoh M, Takei M, Yamanishi T, Hayashi K. Epidemiological Research Committee on Micturition. Epidemiologic survey on urination in Japan. J. Neurogenic Bladder Soc. 2003; 14: 26677.
  • 6
    Homma Y, Ando T, Yoshida M et al. Preparation of a questionnaire for urinary incontinence symptoms (1st report): Presentation of questionnaire. J. Neurogenic Bladder Soc. 2003; 14: 2407.
  • 7
    Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire: Development and psychometric testing. Br. J. Urol. 1996; 77: 80512.
  • 8
    Donovan JL, Abrams P, Peters TJ et al. The ICS-‘BPH’ Study: The psychometric validity and reliability of the ICS male questionnaire. Br. J. Urol. 1996; 77: 55462.
  • 9
    Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992; 148: 154957.
  • 10
    O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology 1997; 49 (Suppl 5): 5863.
  • 11
    Bower WF, Moore KH, Adams RD. A novel clinical evaluation of childhood incontinence and urinary urgency. J. Urol. 2001; 166: 241115.
  • 12
    Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int. 2003; 92: 7417.
  • 13
    Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 2003; 326: 8414.
  • 14
    Freeman R, Hill S, Millard R, Slack M, Sutherst J. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet. Gynecol. 2003; 102: 60511.
  • 15
    Homma Y, Ando T, Yoshida M et al. Voiding and incontinence frequencies: Variability of diary data and required diary length. Neurourol. Urodyn. 2002; 21: 2049.
  • 16
    Schick E, Jolivet-Tremblay M, Dupont C, Bertrand PE, Tessier J. Frequency-volume chart: The minimum number of days required to obtain reliable results. Neurourol. Urodyn. 2003; 22: 926.
  • 17
    Brown JS, McNaughton KS, Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003; 61: 8029.
  • 18
    Ku JH, Jeong IG, Lim DJ, Byun SS, Paick JS, Oh SJ. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: Prospective assessment of patient compliance and burden. Neurourol. Urodyn. 2004; 23: 3315.
  • 19
    Homma Y, Yoshida M, Obara K, Seki N, Yamaguchi O. Development and validity of the Overactive Bladder Symptom Score (OABSS). Jpn J. Urol. 2005; 96: 182.
  • 20
    Homma Y, Matsui K, Yamaguchi O. Lower limits for overactive bladder. J. Neurogenic Bladder Soc. 2004; 15: 109.
  • 21
    Dowd TT, Campbell JM, Jones JA. Fluid intake and urinary incontinence in older community-dwelling women. J. Community Health Nurs. 1996; 13: 17986 (Level IV).
  • 22
    Bryant CM, Dowell CJ, Fairbrother G. A randomised trial of the effects of caffeine upon frequency, urgency and urge incontinence. Neurourol. Urodyn. 2000; 19: 5012 (Level II).
  • 23
    Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. BMJ 1980; 281: 132223 (Level II).
  • 24
    Fantl JA, Wyman JF, McClish DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265: 60913 (Level II).
  • 25
    Wyman JF, Fantl JA, McClish DK, Bump RC. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am. J. Obstet. Gynecol. 1998; 179: 9991007 (Level I).
  • 26
    Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. Br. J. Urol. 1981; 53: 5656 (Level II).
  • 27
    Colombo M, Zanetta G, Scalambrino S, Milani R. Oxybutynin and bladder training in the management of female urinary urge incontinence: A randomized study. Int. Urogynecol. J. 1995; 6: 637 (Level II).
  • 28
    Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J. Am. Geriatr. Soc. 2002; 50: 80816 (Level I).
  • 29
    Burns PA, Pranikoff K, Nochajski TH, Hadley EC, Levy KJ, Ory MG. A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community-dwelling women. J. Gerontol. 1993; 48: M16774 (Level II).
  • 30
    Nygaard IE, Kreder KJ, Lepic MM, Fountain KA, Rhomberg AT. Efficacy of pelvic floor muscle exercises in women with stress, urge and mixed urinary incontinence. Am. J. Obstet. Gynecol. 1996; 174: 1205 (Level II).
  • 31
    Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J. Am. Geriatr. Soc. 2000; 48: 3704 (Level I).
  • 32
    Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA 2002; 288: 229399 (Level I).
  • 33
    Colling J, Ouslander J, Hadley BJ, Eisch J, Campbell E. The effects of patterned urge-response toileting (PURT) on urinary incontinence among nursing home residents. J. Am. Geriatr. Soc. 1992; 40: 13541 (Level I).
  • 34
    Thüroff JW, Chartier-Kastler E, Corcus J et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J. Urol. 1998; 16 (Suppl 1): S4861 (Review).
  • 35
    Amarenco G, Marquis P, McCathy C, Richard F. Quality of life of women with stress urinary incontinence with or without pollakiuria. Presse Med. 1998; 27: 510 (in French) (Level I).
  • 36
    Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 2001; 41: 63644 (Level II).
  • 37
    Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J. Am. Geriatr. Soc. 1998; 46: 813 (Level II).
  • 38
    Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: Special considerations in the geriatric population. Am. J. Manag. Care 2000; 11 (Suppl 6): S599606 (Review).
  • 39
    Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol. 2000; 95: 71821 (Level I).
  • 40
    Appell RA, Sand P, Dmochowski R et al. Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study. Mayo Clin. Proc. 2001; 76: 35863 (Level I).
  • 41
    Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: A randomised trial. Br. J. Obstet. Gynaecol. 1995; 102: 92930 (Level II).
  • 42
    Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J. Urol. 1996; 156: 7536 (Level IV).
  • 43
    Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int. Urogynecol. J. Pelvic Foor Dysfunct. 1998; 9: 1002 (Level IV).
  • 44
    Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Urol. 2002; 168: 5806 (Level I).
  • 45
    Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 23742 (Level I).
  • 46
    Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: A double-blind, placebo-controlled clinical trial. Spinal Cord. 1999; 37: 196200 (Level I).
  • 47
    Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999; 84: 64651 (Level I).
  • 48
    Dorschner W, Stolzenburg JU, Griebenow R et al. Efficacy and cardiac safety of propiverine in elderly patients: A double-blind, placebo-controlled clinical study. Eur. Urol. 2000; 37: 7028 (Level I).
  • 49
    Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int. 2003; 92: 7417 (Level I).
  • 50
    Takei M, Homma Y, the Japanese Tolterodine Study Group. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int. J. Urol. 2005; 12: 45664 (Level V).
  • 51
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care 2002; 8 (Suppl): S608615 (Level I).
  • 52
    Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr. Med. Res. Opin. 2002; 18: 17784 (Level I).
  • 53
    Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. 2002; 50: 799807 (Level I).
  • 54
    Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int. J. Clin. Pract. 2006; 60: 74551 (Level V).
  • 55
    Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: Results from the IMPACT trial. Int. J. Clin. Pract. 2006; 60: 7528 (Level V).
  • 56
    Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int. 2007; 100: 10710 (Level I).
  • 57
    Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J. Urol. 2004; 171: 7526 (Level V).
  • 58
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an [alpha]-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J. Urol. 2003; 169: 22536 (Level II).
  • 59
    Yamaguchi O, Marui E, Kakizaki H et al. On behalf of the Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007; 100: 57987 (Level I).
  • 60
    Yamaguchi O. Long-term safety and efficacy of solifenacin succinate in patients with overactive bladder. Jpn Pharmacol Ther. 2006; 34: S6986 (Level V).
  • 61
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur. Urol. 2005; 48: 46470 (Level I).
  • 62
    Chapple CR, Fianu-Jonsson A, Indig M et al. for the STAR study group. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur. Urol. 2007; 52: 1195203 (Level I).
  • 63
    Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. 2004; 172: 191924 (Level I).
  • 64
    Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int. J. Clin. Pract. 2006; 60: 95966 (Level I).
  • 65
    Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 2005; 95: 815 (Level I).
  • 66
    Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am. J. Geriatr. Pharmacother. 2006; 4: 1424 (Level I).
  • 67
    Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: A pooled analysis. Curr. Med. Res. Opin. 2006; 22: 418 (Level I).
  • 68
    Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int. Urogynecol. J. 2006; 17: 51219 (Level I).
  • 69
    Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis. Eur. Urol. 2005; 48: 4837 (Level I).
  • 70
    Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int. Urogynecol. J. 2007; 18: 73741 (Level I).
  • 71
    Haab F, Cardozo L, Chapple C, Ridder AM; for the Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. 2005; 47: 37684 (Level III).
  • 72
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare Open-Label Trial (VOLT). Clin. Ther. 2006; 28: 193546 (Level V).
  • 73
    Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes. Ann. Pharmacother. 2007; 41: 3919 (Level V).
  • 74
    Michel MC, Wetterauer U, Vogel M, de la Rosette JJMCH. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use. Drug Saf. 2008; 31: 50514 (Level V).
  • 75
    Cardozo L, Nagy G, Kiss L et al. Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int. Urogynecol. J. 2006; 17 (Suppl 2): S889 (Abstr 052) (Level I).
  • 76
    Serels S, Andoh M, Smith N. Solifenacin significantly improves urgency in overactive bladder (OAB) patients compared to placebo. Urology 2006; 68 (Suppl 5A): 72 (Abstr MP-04.11) (Level I).
  • 77
    Toglia M, Andoh M, Hussain I. Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder. Neurourol. Urodyn. 2006; 655: 25 (Abstr 123) (Level I).
  • 78
    Thüroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo. J. Urol. 1991; 145: 81316 (Level I).
  • 79
    Holmes DM, Montz FJ, Stanton SL. Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br. J. Obstet. Gynaecol. 1989; 96: 60712 (Level II).
  • 80
    Ruffmann R. A review of flavoxate hydrochloride in the treatment of urge incontinence. J. Int. Med. Res. 1988; 16: 31730 (Level IV).
  • 81
    Chapple CR, Parkhouse H, Gardener C, Milroy EJ. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br. J. Urol. 1990; 66: 4914 (Level III).
  • 82
    Milani R, Scalambrino S, Milia R et al. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int. Urogynecol. J. 1993; 4: 38 (Level III).
  • 83
    Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986; 15: 299303 (Level II).
  • 84
    Raezer DM, Benson GS, Wein AJ, Duckett JW Jr. The functional approach to the management of the pediatric neuropathic bladder: A clinical study. J. Urol. 1977; 117: 64954 (Level V).
  • 85
    Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol. Res. 2001; 29: 11825 (Review).
  • 86
    Cruz F. Vanilloid receptor and detrusor instability. Urology 2002; 59 (Suppl 5): 5160 (Review).
  • 87
    de Groat WC, Kawatani M, Hisamitsu T et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. 1990; 30 (Suppl): S717 (Review).
  • 88
    Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339: 1239 (Level IV).
  • 89
    de Sèze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: A double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol. Urodyn. 1998; 17: 51323 (Level II).
  • 90
    Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997; 350: 6401 (Level IV).
  • 91
    Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: Long-term results for the treatment of detrusor hyperreflexia. Eur. Urol. 2000; 38: 44452 (Level IV).
  • 92
    Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J. Urol. 2002; 168: 5759 (Level IV).
  • 93
    Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J. Urol. 2003; 170: 8359 (Level IV).
  • 94
    Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J. Uro1. 2002; 167: 171014 (Level III).
  • 95
    de Sèze M, Wiart L, de Sèze MP et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: A double-blind, randomized, controlled study. J. Urol. 2004; 171: 2515 (Level II).
  • 96
    Yokoyama T, Nozaki K, Fujita O, Nose H, Inoue M, Kumon H. Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J. Urol. 2004; 172: 596600 (Level III).
  • 97
    de Sèze M, Petit H, Gallien P et al. Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 2002; 42: 5662 (Level V).
  • 98
    Reitz A, von Tobel J, Stöhrer M et al. European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Neurourol. Urodyn. 2002; 21: 4278 (Level V).
  • 99
    Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J. Urol. 2004; 172: 2403 (Level II).
  • 100
    Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. 2004; 45: 4209 (Level I).
  • 101
    Tršinar B, Kraij B. Maximal electrical stimulation in children with unstable bladder and nocturnal enuresis and/or daytime incontinence: A controlled study. Neurourol. Urodyn. 1996; 15: 13342 (Level I).
  • 102
    Abel I, Ottesen B, Fischer-Rasmussen W, Lose G. Maximal electrical stimulation of the pelvic floor in the treatment of urge incontinence: A placebo-controlled study. Neurourol. Urodyn. 1996; 15: 2834 (Level II).
  • 103
    Bower WF, Moore KH, Adams RD. Randomised sham-controlled trial of two surface neuromodulation sites in women with detrusor instability. Neurourol. Urodyn. 1997; 16: 4289 (Level II).
  • 104
    Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Suda S. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology 2000; 55: 3537 (Level II).
  • 105
    Yasuda K, Kawabe K, Sato A et al. Double-blind crossover study of the TEU-20 interference low-frequency device for urinary frequency, urgency, and incontinence. Jpn J. Urol. Surg. 1994; 7: 297324 (Level II).
  • 106
    Suzuki S, Kawabe K, Kageyama S et al. Long-term clinical use of the TEU-20 interference low-frequency device for urinary frequency, urgency, and incontinence. Jpn J. Urol. Surg. 1994; 7: 52940 (Level V).
  • 107
    Fujishiro T, Takahashi S, Enomoto H, Ugawa Y, Ueno S, Kitamura T. Magnetic stimulation of the sacral roots for the treatment of urinary frequency and urge incontinence: An investigational study and placebo controlled trial. J. Urol. 2002; 168: 10369 (Level II).
  • 108
    Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. 2001; 166: 5503 (Level III).
  • 109
    Abrams P, Cardozo L, Fall M et al. The Standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 16778 (Level V).
  • 110
    Abram P. Detrusor instability and bladder outlet obstruction. Neurourol. Urodyn. 1985; 4: 31728 (Level III).
  • 111
    Bates CP, Whiteside CG, Turner-Warwick R. Synchronous cine/pressure/flow/cysto/urethrography with special reference to stress and urge incontinence. Br. J. Urol. 1970; 42: 71423 (Level IV).
  • 112
    van Waalwijk van Doorn E, Anders K, Khullar V et al. Standardisation of ambulatory urodynamic monitoring: Report of the Standardisation Sub-committee of the International Continence Society for Ambulatory Urodynamic Studies. Neurourol. Urodyn. 2000; 19: 11325 (Level V).
  • 113
    Wein AJ. Overactive bladder: Defining the disease. Am. J. Manag. Care 2000; 6 (11 Suppl): S55964 (Level V).
  • 114
    Research Group on the Standardization of Urological Treatment (ed.) EBM-based Guidelines for the Treatment of Benign Prostatic Hyperplasia. Tokyo: Jiho, 2001 (Level V).
  • 115
    Gormley EA, Griffiths DJ, McCracken PN, Harrison GM, McPhee MS. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol. Urodyn. 1993; 12: 44553 (Level V).
  • 116
    Nitti VW, Kim Y, Combs AJ. Voiding dysfunction following transurethral resection of the prostate: Symptoms and urodynamic findings. J. Urol. 1997; 157: 6003 (Level V).
  • 117
    Thomas AW, Cannon A, Barlett E, Ellis-Jones J, Abrams P. The long term urodynamic follow-up of TURP: A study of the prevalence of detrusor instability. J. Urol. 1999; 161 (Suppl): 257 (Level V).
  • 118
    Bosch JL. Urodynamic effects of various treatment modalities for benign prostatic hyperplasia. J. Urol. 1997; 158: 203444 (Level V).
  • 119
    Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J. Urol. 2002; 168: 6059 (Level IV).
  • 120
    Dmochowski RR, Staskin D. Overactive bladder in men: Special considerations for evaluation and management. Urology 2002; 60 (Suppl 5): 5662 (Level IV).
  • 121
    Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999; 36: 113 (Level I).
  • 122
    Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: A stratified analysis. Urology 1997; 49: 197206 (Level I).
  • 123
    Gerber GS, Kim JH, Contreras BA, Steinberg GD, Rukstalis DB. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996; 47: 8404 (Level IV).
  • 124
    Gerber GS, Contreras BA, Zagaja GP, Kim JH, Steinberg GD, Rukstalis DB. Doxazosin in men with lower urinary tract symptoms: Urodynamic evaluation at 15 months. Urology 1997; 50: 22933 (Level IV).
  • 125
    Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J. Urol. 2002; 167 (Suppl): 266 (Level IV).
  • 126
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J. Urol. 2003; 169: 22536 (Level II).
  • 127
    Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006; 296: 231928 (Level I).
  • 128
    Brubaker L. Electrical stimulation in overactive bladder. Urology 2000; 55 (Suppl 5): 1723 (Level V).
  • 129
    Yamanishi T, Sakakibara R, Uchiyama T et al. Comparative study of the effects of magnetic versus electrical stimulation on inhibition of detrusor overactivity. Urology 2000; 56: 77781 (Level II).